Resa K. Schlossberg

Ms. Schlossberg structures, drafts, negotiates and advises on joint ventures, strategic alliances, mergers and acquisitions, and agreements such as license, research and development (R&D), collaboration, co-marketing and co-promotion, manufacturing and supply, R&D funding, synthetic royalty deals and consulting. She also conducts IP diligence and evaluates technologies for clients, including pharmaceutical, chemical, biotechnology, cosmetic, medical device and renewable energy companies, among others. In addition to transactional work, Ms. Schlossberg has significant experience litigating patent infringement disputes in U.S. federal court, representing clients in false advertising and consumer deception matters and counseling on various strategic IP issues. She is a registered patent attorney with the U.S. Patent and Trademark Office.

Ms. Schlossberg was named one of the Top 250 Women in IP and a Transactions Star by Managing IP in 2023 and has been named to Intellectual Asset Management’s IAM Patent 1000, where she is described as a “master at executing a deep dive into target and competitor portfolios, formulating strategies, structuring deals and successfully negotiating them.”

She is a member of Skadden’s Diversity, Equity & Inclusion Committee and previously served as a hiring partner and co-chair of the Hiring and Summer Associate committees for the firm’s New York office.

Representative transactions include:

• Achillion in its $930 million sale to Alexion
• Alcon in its $753 million acquisition of Aerie Pharmaceuticals, Inc. and its $355 million acquisition of the U.S. commercialization rights to SIMBRINZA from Novartis AG
• Alder BioPharmaceuticals in its sale to Lundbeck for up to $1.95 billion
• Alnylam Pharmaceuticals, Inc. in its $2.8 billion co-development and co-commercialization agreement with Roche Holding AG to develop and commercialize its hypertension drug Zilebesiran
• Amicus Therapeutics, Inc. in ARYA Sciences Acquisition Corp IV’s acquisition of Amicus’ gene therapy business
• Anokion in its exclusive strategic collaboration with Celgene to develop novel tolerance-inducing therapeutics for autoimmune diseases
• ArQule in its $2.7 billion sale to Merck
• Array Biopharma, Inc. in its strategic collaborations with Bristol-Myers Squibb and Merck
• Aspen Technology in its $11 billion merger with Emerson Electric Company’s software business units
• BELLUS Health Inc. in its $2 billion acquisition by GSK plc
• BridgeBio Pharma, Inc. in its $1 billion acquisition of all the outstanding common stock of Eidos Therapeutics, Inc. that it did not already own
• Brookfield Super-Core Infrastructure Partners in its $2.4 billion acquisition of a 19.9% minority interest in FirstEnergy Transmission, LLC
• ByteDance in its investment and business cooperation agreement with For Fun Labs, Inc. and various other transactions
• Celularity in its acquisition by GX Acquisition Corp., a special purpose acquisition company
• CerSci Therapeutics Inc. in its acquisition by ACADIA Pharmaceuticals Inc. for $53 million upfront and contingent payments of $887 million
• DENTSPLY SIRONA Inc. in its $131 million acquisition of substantially all of the assets of Propel Orthodontics, LLC
• Dicerna Pharmaceuticals, Inc. in its acquisition by Novo Nordisk A/S at an equity value of $3.3 billion
• DowDuPont in its separation into three independent public companies
• DuPont in several matters, including its merger of its Nutrition and Health Business with IFF through a reverse Morris trust transaction; $11 billion sale of the majority of its Mobility & Materials (M&M) business to Celanese Corp.; and sale of a portion of its crop protection business to FMC Corporation in exchange for substantially all of FMC’s health and nutrition business and a balancing payment of $1.625 billion
• Exelixis in its exclusive clinical development collaboration and option agreement with Sairopa to develop ADU-1805
• Endo Pharmaceuticals in various strategic collaborations, acquisitions and other matters, including its sale of its men’s health business to Boston Scientific and its acquisition of Penwest Pharmaceuticals
• Everest Medicines Limited in its $451 million IPO of shares and listing on the Hong Kong Stock Exchange
• FaZe Clan Inc. in its $1 billion combination with special purpose acquisition company B. Riley Principal 150 Merger Corp.
• Gain Therapeutics, Inc. in its $40 million IPO of common stock
• Gilead Sciences in its $4.9 billion acquisition of Forty Seven, $11.9 billion acquisition of Kite Pharma and acquisition of Cell Design Labs for up to $567 million
• GX Acquisition Corp. in its merger with Celularity Inc. at an enterprise value of $1.7 billion. As a result of the merger, Celularity became a publicly traded company
• Hasbro in its $522 million acquisition of Saban Brands’ “Power Rangers” and other entertainment assets
• Intercept Pharmaceuticals, Inc. in various capital markets matters
• Iora Health in its $2.1 billion acquisition by One Medical
• IVERIC bio, Inc. in its $5.9 billion acquisition by Astellas Pharma Inc.
• Juno Therapeutics, Inc. in its acquisition by Celgene Corporation, valuing Juno at over $11 billion
• a life sciences startup in a sponsored research agreement with an academic institution
• Medigene AG in its multi-target research collaboration with BioNTech Se to develop T cell receptor (TCR)-based immunotherapies against cancer
• Nano-X Imaging Ltd in its initial public offering
• OceanSound Partners, LP in its strategic investment in Lynx Software Technologies and various other transactions
• Orum Therapeutics in Bristol-Myers Squibb’s acquisition of Orum’s ORM-6151 leukemia antibody treatment program
• Pandion Therapeutics in its pending $1.8 billion sale to Merck
• Permira Funds in several acquisitions, including of Cambrex Corporation, a majority stake in Reformation and Lyophilization Services of New England, Inc., as well as the sales of its portfolio companies Atrum Innovations and PHARMAQ Holding AS
• Pfizer Inc. in its proposed $160 billion combination with Allergan; proposed but withdrawn $115 billion acquisition of AstraZeneca through the formation of a new U.K. holding company; IPO of its animal health business and related R&D collaboration and license agreement and IP license agreements between Pfizer Inc. and Zoetis Inc.; R&D agreements with NovaQuest and RPI Finance Trust; exclusive agreement granting AROG Pharmaceuticals worldwide rights to a small molecule inhibitor of PDGFr; and collaboration to co-develop Tremelimumab for advanced melanoma
• Population Council in its license agreement with TherapeuticsMD
• Purdue Pharma L.P. in its sale of an active pharmaceutical ingredient (API) manufacturing facility and corresponding negotiation of a long-term API supply agreement with the facility purchaser and an agreement with stalking horse bidder Atlantis Consumer Healthcare to sell the assets of Avrio Health L.P. for up to $397 million via an auction process pursuant to Section 363 of the Bankruptcy Code
• Stemline Therapeutics in its sale to Menarini Group for up to $677 million
• Stryker Corporation in its acquisition of privately held CHG Hospital Beds, Inc. and various other matters
• TriRx Pharmaceutical Services in its acquisition of the French manufacturing and packaging operations of Merck & Co., Inc.’s animal health business and a related long-term supply agreement
• Vertex Pharmaceuticals in its $950 million acquisition of Semma Therapeutics and $320 million acquisition of ViaCyte
• vTv Therapeutics Inc. (a MacAndrews & Forbes portfolio company) in its collaboration, license and investment arrangements with affiliates of G42 Healthcare, and its investment and services arrangement with CinRx Pharma
• VYNE Therapeutics Inc. in its $50 million offering of common stock
• Wendel SE in its $910 million acquisition of Crisis Prevention Institute from FFL Partners